Starting a Patient on Jakafi
Dose optimization is key to maintaining the balance between safety and efficacy.

START with the appropriate dose
A complete blood count (CBC) and platelet (PLT) count must be performed before initiating therapy.1
A complete blood count (CBC) and platelet (PLT) count must be performed before initiating therapy.1


Jakafi is also available in tablets of






MONITOR: Monitoring patients after initiation of Jakafi is essential
MONITOR: Monitoring patients after initiation of Jakafi is essential
A CBC and PLT count must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.1
…of patients treated with Jakafi in the RESPONSE* trial had dose adjustments from the recommended starting dose by week 322

OPTIMIZE: Individualize dosing of Jakafi to optimize the balance between safety and efficacy1
OPTIMIZE: Individualize dosing of Jakafi to optimize the balance between safety and efficacy1
A CBC and PLT count must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.1
…of patients randomized to Jakafi discontinued treatment due to an adverse event1,3
Dosing in patients with renal or hepatic impairment, or when coadministered with strong CYP3A4 inhibitors or fluconazole1
For further information and to download the Jakafi dosing guide, click here.
Video
Dosing of Jakafi® (ruxolitinib) in Patients With Polycythemia Vera Who Have Had an Inadequate Response to or Are Intolerant of Hydroxyurea
Hematology specialist Dr Harry Erba discusses the appropriate dosing of Jakafi® (ruxolitinib) in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Dr Erba addresses the recommended starting dose, dose reductions based on hemoglobin levels and/or platelet counts, and dose modifications because of insufficient response in PV.

*The RESPONSE (Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bEst available care) trial was a randomized, open-label, active-controlled phase 3 trial comparing Jakafi with best available therapy (BAT) in 222 patients with polycythemia vera. BAT included hydroxyurea (60%), interferon/pegylated interferon (12%), anagrelide (7%), pipobroman (2%), lenalidomide/thalidomide (5%), and observation (15%). Patients enrolled in the study had been diagnosed with polycythemia vera for at least 24 weeks, had an inadequate response to or were intolerant of hydroxyurea, required phlebotomy for hematocrit (Hct) control, and exhibited splenomegaly. All patients were required to demonstrate Hct control between 40% and 45% prior to randomization. After week 32, patients were able to cross over to Jakafi treatment. The composite primary endpoint was defined as Hct control without phlebotomy eligibility and a ≥35% spleen volume reduction as measured by CT or MRI. To achieve the Hct control endpoint, patients could not become eligible for phlebotomy between weeks 8 and 32. Phlebotomy eligibility was defined as Hct >45% that is ≥3 percentage points higher than baseline or Hct >48% (lower value). 23% of patients receiving Jakafi achieved the composite primary endpoint at week 32 vs <1% for BAT (P <0.0001).1,3
References
- Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation.
- Data on file. Incyte Corporation. Wilmington, DE.
- Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.